$ Value
$5K
Shares
323
Price
$14
Filed
Dec 5
Insider
Name
Capps Kathleen S.
Title
See Remarks
CIK
0002085127
Roles
Transaction Details
Transaction Date
2025-12-05
Code
S
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
8,377
Footnotes
Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 23, 2022 and November 22, 2023, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Filing Info
Capps Kathleen S.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-12-05 | ENTA | ▼ | $5K |
| 2025-12-02 | ENTA | ▼ | $3K |
| 2025-12-01 | ENTA | F | $1K |
| 2025-11-25 | ENTA | A | $0 |
| 2025-11-25 | ENTA | A | $0 |
Other Insiders at ENTA (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| CARTER BRUCE L A | — | — | 2026-03-11 |
| FOLETTA MARK G | — | — | 2026-03-11 |
| Russell Lesley | — | — | 2026-03-11 |
| Peterson Kristine | — | — | 2026-03-11 |
|
Luly Jay R.
President and CEO
|
— | — | 2026-02-12 |
|
Or Yat Sun
Chief Scientific Officer
|
— | — | 2026-02-12 |
| Vance Terry | — | — | 2026-03-11 |
| Hata Yujiro S | — | — | 2026-03-11 |
|
Kowalsky Matthew Paul
Chief Legal Officer
|
— | — | 2026-02-12 |
|
Kieffer Tara Lynn
Chief Product Strategy Officer
|
— | — | 2026-02-12 |
|
Luu Brendan
Chief Business Officer
|
— | — | 2026-02-12 |
|
Rottinghaus Scott T.
Chief Medical Officer
|
— | — | 2026-02-12 |